LUCISOT User Guide Overview

LUCISOT (LUCISOT), as an oral small molecule inhibitor, can accurately target and lock the KRAS G12C mutant protein, keeping it in an inactive state, thereby effectively curbing the proliferation and spread of tumor cells. In view of the high price of the original drug, the launch of LUCISOT provides patients with a more economical and feasible treatment option. The following is a condensed overview of the instructions for use of LUCISOT, designed to provide patients with detailed and precise information.

1. Basic overview of drugs

Product name:LUCISOT

Specification details: per tablet120 mg, 56 tablets per box

Price range: Each box is about one to two thousand yuan. The specific price may vary due to regional differences and sales channels.

2. Applicable symptoms and medication guidance

1. Applicable symptoms:LUCISOT is mainly used to treat adult patients with KRAS G12C mutant locally advanced or metastatic non-small cell lung cancer, and the patients must have experienced at least one systemic treatment.

2. Medication instructions: It is recommended to take 960 mg orally once a day (i.e. 8 120 mg tablets). The best time to take it is at the same time every day, without dietary restrictions. Tablets should be swallowed whole and avoid chewing, crushing or splitting.

3. Important matters needing attention

1. Gene testing: Before usingLUCISOT, patients need to undergo genetic testing for KRAS G12C mutation to ensure the suitability of the drug.

2. Liver function monitoring: Liver function tests should be performed every three weeks in the initial stage of treatment (the first three months), and then once a month. Depending on hepatotoxicity, dose adjustment or discontinuation may be necessary.

3. Interstitial lung disease monitoring: Patients should pay close attention to pulmonary symptoms. If suspected interstitial lung disease/pneumonitis occurs, the drug should be discontinued immediately and permanent discontinuation should be considered.

4. Drug interactions: Patients need to inform their doctors about all the drugs they are taking to avoid the risk of potential drug interactions.

5. Adverse reactions: Common adverse reactions include diarrhea, musculoskeletal pain, nausea, fatigue, liver toxicity and cough, etc., most of which are mild to moderate. A small number of patients may experience serious side effects and require close monitoring and prompt medical treatment.

4. Storage conditions description

1. Recommended storage temperature: It is recommended to store between20°C to 25°C, but it can also be stored for short periods in the temperature range of 15°C to 30°C.

2. Safe storage measures: Please keep away from children and strictly follow the storage instructions on the drug packaging.

In summary, Lucisot (LUCISOT) provides an affordable and effective treatment option for patients with KRAS G12C mutant non-small cell lung cancer. However, during use, patients must strictly abide by medical instructions and instructions, closely monitor adverse reactions, and communicate with doctors regularly to ensure the safety and effectiveness of treatment.